参考文献/References:
［1］ Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer［J］. Nature, 2019, 574:268-272.
［2］ Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer［J］. J Hepatol, 2019, 71: 616-630.
［3］ Omata M, Cheng AL, Kokudo N, et al. Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update［J］. Hepatol Int, 2017, 11: 317-370.
［4］ Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update［J］. Hepatol Res, 2019, 49: 1109-1113.
［5］ 张 浩，仲富瑞，程宦立，等. 肝动脉灌注化疗栓塞联合射频消融治疗中晚期肝癌的疗效分析［J］. 中国普通外科杂志，2020，29：35-42．
［6］ Kim AR, Park E, Kwon SY, et al. Efficacy and safety of combined radiofrequency ablation with transarterial chemoembolization in patients with Barcelona clinic liver cancer stage A hepatocellular carcinoma ineligible for curative treatment［J］. Korean J Gastroenterol, 2019, 73: 167-176.
［7］ Li J, Wang N, Shi C, et al. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma［J］. J Cancer Res Ther, 2021, 17: 733-739.
［8］ 侯勤明，王国伟，任鲜华，等. 基于CalliSpheres载药微球的肝动脉栓塞化疗治疗不可切除的原发性肝癌［J］. 浙江实用医学，2019，24：431-433．
［9］ 王砚亮，宋 威，卞益同，等. CalliSpheres载药微球与常规TACE在治疗原发性肝癌中的临床疗效及安全性对比［J］. 临床放射学杂志，2020，39：1853-1859．
［10］ 中国抗癌协会肝癌专业委员会，中华医学会肝病学分会肝癌学组，中国抗癌协会病理专业委员会，等. 原发性肝癌规范化病理诊断指南(2015年版)［J］. 解放军医学杂志，2015，40：865-872.
［11］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45:228-247.
［12］ Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)［J］. JAMA Oncol, 2015, 1: 1051-1059.
［13］ Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-pacific primary liver cancer expert consensus statements［J］. Liver Cancer, 2020, 9: 245-260.
［14］ 寸江平，姜永能，宗 璇，等. CalliSpheres微球联合空白微球TACE治疗中晚期肝癌的近期疗效及安全性研究［J］. 介入放射学杂志，2019，28：237-241．
［15］ Zhang X, Zhou J, Zhu DD, et al. CalliSpheres? drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study［J］. Clin Transl Oncol, 2019, 21: 167-177.
［16］ Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma［J］. J Cancer, 2020, 11: 4534-4541.
［17］ Ma Y, Zhao C, Zhao H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres? microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients［J］. Am J Transl Res, 2019, 11: 7456-7470.
［18］ Zuo MX, Huang JH. The history of interventional therapy for liver cancer in China［J］. J Interv Med, 2018, 1: 70-76.
［19］ Qian K, Zhang F, Allison SK, et al. Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: current status［J］. J Interv Med, 2021, 4: 1-7.
相似文献/References:
[1]官泳松,贺庆.肝癌介入治疗中应用p５３的几个要点[J].介入放射学杂志,2008,(11):761.
GUAN Yongsong,HE Qing.Essentials in clinical application of p５３for tumors intervention－example of liver cancer[J].journal interventional radiology,2008,(02):761.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].journal interventional radiology,2010,(02):382.
[3]高 嵩,朱旭,杨仁杰,等. ＴＡＣＥ联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
,,et al. ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｈｅｐａｔｉｃ ａｒｔｅｒｉａｌ ｉｎｆｕｓｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｕｓｉｎｇ ｏｘａｌｉｐｌａｔｉｎ， ５ｆｌｕｏｒｏｕｒａｃｉｌ ａｎｄ ｆｏｌｉｎｉｃ ａｃｉｄ ｆｏｒ ｉｎｔｅｒｍｅｄｉａｔｅ ａｎｄ ａｄｖａｎｃｅｄ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ[J].journal interventional radiology,2012,(02):377.
[4]程洪涛,郭晨阳,黎海亮,等.ＴＡＣＥ联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ＣＴｇｕｉｄｅｄ ｐｅｒｃｕｔａｎｅｏｕｓ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａｎ ａｎａｌｙｓｉｓ ｏｆ ｆａｃｔｏｒｓ ａｆｆｅｃｔｉｎｇ ｔｈｅ ｔｈｅｒａｐｅｕｔｉｃ ｒｅｓｕｌｔ [J].journal interventional radiology,2012,(02):216.
[5]张晓前,郭 鹏,党之俊,等.金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J].介入放射学杂志,2012,(03):249.
,,et al.Ｋｉｎｇｌｏｎｇ ｃａｐｓｕｌｅｓ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｉｎｔｅｒｖｅｎｔｉｏｎａｌ ｔｈｅｒａｐｙ ｆｏｒ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｃｌｉｎｉｃａｌ ｏｂｓｅｒｖａｔｉｏｎ [J].journal interventional radiology,2012,(02):249.
[6]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合ＣＴ引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
,,et al.Ｓｅｑｕｅｎｔｉａｌ ｔｒｅａｔｍｅｎｔ ｗｉｔｈ ＴＡＣＥ ａｎｄ ＣＴｇｕｉｄｅｄ ＲＦＡ ｆｏｒ ｓｍａｌｌ ａｎｄ ｍｏｄｅｒａｔｅ ｓｉｚｅｄ ＨＣＣ [J].journal interventional radiology,2012,(02):301.
[7]姚全军,胡鸿涛,黎海亮,等.Ｃ臂ＣＴ成像在乏血供原发性肝癌诊疗中的临床应用[J].介入放射学杂志,2012,(04):305.
,,et al.Ｔｈｅ ｃｌｉｎｉｃａｌ ａｐｐｌｉｃａｔｉｏｎ ｏｆ Ｃ ａｒｍ ＣＴ ｉｍａｇｉｎｇ ｉｎ ｄｉａｇｎｏｓｉｎｇ ａｎｄ ｔｒｅａｔｉｎｇ ｈｙｐｏｖａｓｃｕｌａｒ ｐｒｉｍａｒｙ ｈｅｐａｔｉｃ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(02):305.
[8]刘 昕,吕维富,鲁 东,等. 动脉介入栓塞治疗肝癌破裂出血[J].介入放射学杂志,2012,(07):586.
LIU Xin,LV Wei- fu,LU Dong,et al. Interventional treatment of hepatic bleeding due to spontaneous rupture of hepatocellular carcinoma[J].journal interventional radiology,2012,(02):586.
[9]张志良,杨学东,温阿明,等. 经动脉化疗栓塞联合伽玛刀治疗原发性肝癌的疗效评价[J].介入放射学杂志,2012,(07):596.
ZHANG Zhi- liang,YANG Xue- dong,WEN A-ming,et al. Evaluation of TACE combined with gamma?蛳 knife radiotherapy for primary hepatocellular carcinoma[J].journal interventional radiology,2012,(02):596.
[10]赵许亚,周 石.TACE联合经皮瘤内注射碘油吡柔比星乳剂治疗中晚期肝癌疗效分析[J].介入放射学杂志,2012,(08):675.
ZHAO Xu- ya,ZHOU Shi.. Transcatheter artery chemoembolization combined with percutaneous intratumoral injection of Lipiodol emulsion of pirarubicin for advanced hepatocellular carcinomas： an analysis of clinical efficacy[J].journal interventional radiology,2012,(02):675.